tweenvest

Lycia Therapeutics, Inc. (NasdaqGS: LYCA)

Health Care · Biotechnology · US

$30.92

+8.07% today · +3.1% 1Y

Public summary
A free snapshot of Lycia Therapeutics, Inc., with figures as of Nov 15, 2026. The full analysis is in the app.Open in the app

Lycia Therapeutics, Inc. (NasdaqGS: LYCA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.78B and employs 65 people.

Over the last twelve months the share price has gained 3.1%, trading between 25.05 and 32.83.

Tweenvest scores Lycia Therapeutics, Inc. across four factors: quality 49/100, value 100/100. Its strongest factor is value.

LYCA price history

Oct 23, 2026 · 30.00Weekly closes 26.40 – 31.20Nov 17, 2026 · 30.92

Key figures

Market cap
$1.78B
Revenue (TTM)
$4.44M
P/E
-59.39
EPS
-2.08
Dividend yield
—
Beta (5Y)
—
52-week high
$32.83
52-week low
$25.05
Avg volume (3M)
—
Shares outstanding
57.68M
Employees
65
Next earnings
—

About Lycia Therapeutics, Inc.

Lycia Therapeutics, Inc. operates as a clinical-stage biotechnology company. It engages in the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory, and allergic diseases. The company was founded in 2019 and is headquartered in South San Francisco, CA.

ISIN
US55081P1003
Founded
2019
Listed since
Oct 23, 2026
Exchange
Nasdaq Global Select
Currency
USD
CompanyMarket capPriceDay
Sino Biological,Inc.SZSE: 301047$1.81BCN¥99.20-11.02%
Ultragenyx Pharmaceutical Inc.NasdaqGS: RARE$1.80B$17.73+6.23%
Zymeworks Inc.NasdaqGS: ZYME$1.80B$26.04+0.81%
Pell Bio-Med Technology Co., Ltd.TWSE: 6949$1.79BNT$45.00+9.89%
Agios Pharmaceuticals, Inc.NasdaqGS: AGIO$1.78B$29.68-0.70%
Recursion Pharmaceuticals, Inc.NasdaqGS: RXRX$1.76B$2.83+3.86%
Stoke Therapeutics, Inc.NasdaqGS: STOK$1.75B$26.68+1.83%
Nurix Therapeutics, Inc.NasdaqGM: NRIX$1.69B$15.48-0.77%

Browse every Biotechnology company →